Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 487

NCT06948435

ArmPopulationDoseWeeksEstimandWeight change
OrforglipronObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r